A RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CYBORD) COMPARED WITH CYBORD ALONE IN NEWLY DIAGNOSED SYSTEMIC AL AMYLOIDOSIS
- Registry ID
- 54767414AMY3001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- JANSSEN INC
- Start date
- 2018-09-26
- Last update
- 2017-12-28
Conditions
Related clinical trials
- A PHASE 1B/2 STUDY OF AZD0120 (ALSO KNOWN AS GC012F), A CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY TARGETING CD19 AND B-CELL MATURATION ANTIGEN (BCMA) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY AL AMYLOIDOSIS
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF INTRATHECALLY ADMINISTERED ALN-APP IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY (CAA)
- A PHASE 2, MULTICOHORT STUDY OF DARATUMUMAB-BASED THERAPIES IN PARTICIPANTS WITH AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS
- A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF BIRTAMIMAB PLUS STANDARD OF CARE VS. PLACEBO PLUS STANDARD OF CARE IN MAYO STAGE IV SUBJECTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS
- A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAEL-101 AND PLASMA CELL DYSCRASIA TREATMENT VERSUS PLACEBO AND PLASMA CELL DYSCRASIA TREATMENT IN PLASMA CELL DYSCRASIA TREATMENT-NAÏVE PATIENTS WITH MAYO STAGE IIIB AL AMYLOIDOSIS
- A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAEL-101 AND PLASMA CELL DYSCRASIA TREATMENT VERSUS PLACEBO AND PLASMA CELL DYSCRASIA TREATMENT IN PLASMA CELL DYSCRASIA TREATMENT-NAÏVE PATIENTS WITH MAYO STAGE IIIA AL AMYLOIDOSIS
View on source registry